Submit Manuscript httpwwwwjgnetcomesps World J Gastroenterol 2017 March 14 2310 17961803 DOI 103748wjgv23i101796 ISSN 10079327 print ISSN 22192840 online Basic Study ECRG2 enhances anticancer effects cisplatin cisplatinresistant esophageal cancer cells upregulation p53 downregulation PCNA ORIGINAL ARTICLE XinFang Hou LinPing Xu HaiYan Song Shuai Li Chen Wu JuFeng Wang XinFang Hou Shuai Li Chen Wu JuFeng Wang Department Medical Oncology Affiliated Cancer Hospital Zhengzhou University Henan Cancer Hospital Zhengzhou 450008 Henan Province China LinPing Xu Department Science Research Affiliated Cancer Hospital Zhengzhou University Henan Cancer Hospital Zhengzhou 450008 Henan Province China HaiYan Song Key Laboratory Medical Tissue Regeneration Henan Province College Basic Medicine Xinxiang Medical University Xinxiang 453003 Henan Province China Supported Public Welfare Project Foundation Henan Province No 20130010 Institutional review board statement The study reviewed approved Henan Cancer Hospital Institutional Review Board Conflictofinterest statement To best knowledge conflict exists Data sharing statement There additional data available relation manuscript OpenAccess This article openaccess article selected inhouse editor fully peerreviewed external reviewers It distributed accordance Creative Commons Attribution Non Commercial CC BYNC 40 license permits distribute remix adapt build work noncommercially license derivative works different terms provided original work properly cited use noncommercial See httpcreativecommonsorg licensesbync40 Manuscript source Unsolicited manuscript Correspondence Dr JuFeng Wang Professor Department Medical Oncology Affiliated Cancer Hospital Zhengzhou University Henan Cancer Hospital 127 Dongming Road Zhengzhou 450008 Henan Province China 13783583966163com Telephone 8637165587598 Fax 8637165587598 Received November 30 2016 Peerreview started December 2 2016 First decision December 19 2016 Revised January 6 2017 Accepted January 18 2017 Article press January 18 2017 Published online March 14 2017 Abstract AIM To explore antitumor effects esophageal cancer related gene 2 ECRG2 combination cisplatin DDP DDPresistant esophageal cancer cells EC9706DDP METHODS A drugresistant cell model established EC9706DDP cells treated ECRG2 DDP Cell viability examined MTT assay The rate cell apoptosis determined flow cytometry The mRNA expression levels proliferating cell nuclear antigen PCNA metallothionein MT p53 determined RTPCR PCNA MT p53 protein expression levels determined western blotting RESULTS The antiproliferative effect ECRG2 combination DDP superior compared ECRG2 DDP The inhibition rate combination reached peak 5133 96 h The early apoptotic rates control ECRG2 DDP ECRG2 plus DDP groups 571 027 1268 061 1415 087 2796 WJGwwwwjgnetcom 1796 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells 036 respectively Although treatment groups significantly different control group P 005 combination treatment ECRG2 plus DDP performed significantly better compared ECRG2 DDP P 005 The combination ECRG2 DDP significantly upregulated p53 mRNA protein levels downregulated PCNA mRNA protein levels compared ECRG2 DDP P 005 However changes seen expression MT mRNA protein CONCLUSION ECRG2 combination DDP inhibit viability induce apoptosis esophageal cancer DDPresistant cells possibly upregulation p53 expression downregulation PCNA expression These findings suggest combination ECRG2 DDP promising strategy clinical treatment esophageal cancers resistant DDP Key words Esophageal cancer relatedgene 2 Cisplatin Resistance p53 Proliferating cell nuclear antigen The Authors 2017 Published Baishideng Publishing Group Inc All rights reserved Core tip Cisplatin DDP effective agents treating esophageal cancer drug resistance poses major impediment Combination therapy important method overcoming drug resistance This study showed esophageal cancerrelated gene 2 ECRG2 combination DDP inhibit viability induce apoptosis DDPresistant esophageal cancer cells possibly upregulation p53 expression downregulation proliferating cell nuclear antigen expression These findings suggest combination ECRG2 DDP promising strategy clinical treatment esophageal cancers resistant DDP Hou XF Xu LP Song HY Li S Wu C Wang JF ECRG2 enhances anticancer effects cisplatin cisplatin resistant esophageal cancer cells upregulation p53 downregulation PCNA World J Gastroenterol 2017 2310 17961803 Available URL httpwwwwjgnet com10079327fullv23i101796htm DOI httpdxdoi org103748wjgv23i101796 INTRODUCTION Esophageal cancer severe global health problem incidence ranks eighth malignant cancers1 In spite improvements early stage detection tumors advanced stage initial diagnosis2 Cisplatin DDPbased doublets commonly treatment regimen patients locally advanced metastatic esophageal cancer36 Unfortunately DDP resistance doselimiting effects challenge improvement treatment s efficacy These obstacles novel combination therapeutic approaches order achieve high therapeutic efficacy lower drug dose7 Esophageal cancer related gene 2 ECRG2 separated identified mRNA technique differential display normal esophageal tissues esophageal cancer tissues 19988 It reported ECRG2 inhibits tumor cell growth promotes cell apoptosis vivo vitro910 In previous study ECRG2 combined DDP enhanced inhibitory effect EC9706 cell proliferation increased inductive effect EC9706 cell apoptosis compared ECRG2 alone11 This suggests ECRG2 involved drug resistance esophageal cancer There currently known studies literature examining effects ECRG2 drug resistance esophageal cancer In present study established drugresistant cell model explore effects ECRG2 drug resistant cells MATERIALS AND METHODS Cell culture reagents PCNA p53 MT primers ECRG2 protein manufactured Sangon Biological Engineering Co Ltd Shanghai China DDP bought Qilu Pharmaceutical Co Ltd Jinan China RPMI 1640 medium fetal bovine serum FBS purchased HyClone Logan UT United States 345Dimethylthiazol2yl25diphenyl tetrazolium bromide MTT TRIzol annexin VFITC apoptosis detection kits purchased Sigma Co St Louis MO United States The reverse transcription amplification kits purchased Promega Co Madison WI United States The rabbit anti human PCNA p53 antibodies purchased Santa Cruz Biotechnology Santa Cruz CA United States The rabbit antihuman MT goat anti rabbit IgG antibodies purchased Abcam Cambridge United Kingdom The human esophageal cancer cell line EC9706 provided tumor cell library Academy Medical Sciences China Establishment drugresistant cell line We shocked EC9706 cells logarithmic phase final concentration 2 mgL DDP We discarded culture solution 48 h washing 3 times PBS The cells cultured fresh nutrient solution washed 2 d remove dead cells When cells reached stable growth increased DDP concentration repeated cells maintained growth medium concentration 05 mgL DDP The cells cultured RPMI1640 medium containing 10 fetal bovine serum 100 Um penicillin WJGwwwwjgnetcom 1797 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells y t l b v l l e C 100 90 80 70 60 50 40 30 20 10 0 EC9706 EC9706DDP 0 1 2 4 8 16 32 Cisplatin concentration μgmL Figure 1 Survival rate EC9706 EC9706cisplatin DDP cells treated concentrations DDP A dosedependent association survival rate EC9706 EC9706DDP cells concentration DDP observed The survival EC9706 cells significantly lower compared EC9706DDP cells following treatment concentrations DDP The IC50 DDP EC9706 cells 334 027 μgmL IC50 DDP EC9706DDP cells 1683 146 μgmL 100 UmL streptomycin 05 mLL DDP humidified incubator 37 5 CO2 Cell viability Drug sensitivity analyzed MTT assay The cells plated 1 103 cellsmL 96well plates volume 100 μL incubated 24 h The media discarded cells treated concentrations DDP ECRG2 72 h A total 20 μL 5 gL MTT solution added cells incubated 4 h 37 The medium discarded 150 μL dimethyl sulfoxide added shaken completely dissolve bluepurple precipitate MTT A microplate reader test absorbance OD 490 nm average values obtained Cell viability calculated formula OD treated wellOD blankOD control wellOD blank 100 Cell apoptosis assay annexinV FITCPI The cells seeded 6well plate density 4 105 cells After overnight attachment cells treated ECRG2 andor DDP 24 h The cells harvested trypsinization washed cold PBS centrifuged 1 103 rpm 5 min resuspended 1 binding buffer 500 μL sample solution added 5 μL FITC conjugated annexinV 10 μL PI followed incubation 15 min dark room temperature The samples measured flow cytometry RNA isolation RTPCR Each group cells collected 24 h drug treatment The total RNA extracted group cells TRIzol reagent according manufacturers protocol The cDNA protocol Reverse Transcription System RT PCR The primers PCNA 5ACCGCTGCGACC GCAATTTG3forward 5ACGTGCAAATTCACC AGAAGGCATC3reverse The primers MT 5CGGATCCAGACTCAAACAGGCTTTTAT3 forward 5CGGATCCCGGAATGGACCCCAACTGCT3 reverse The primers p53 5ATTTGCGTGTG GAGTATTTGG3 forward 5GCTGTTCCGTCCCAGT AGATTA3 reverse The primers GAPDH 5TCATGGGTGTGAACCATGAGAA3 forward 5GGCATGGACTGTGGTCATGAG3 reverse PCR amplification performed kit following conditions 95 5 min followed 30 cycles 95 40 s 55 40 s 72 1 min The expression level mRNA encoding p53 PCNA MT genes evaluated normalized relative GAPDH Western blot The cells collected group lysed 200 μL 1 Tween 20 PBS cycles freezing thawing The insoluble proteins removed centrifugation After quantification total protein protein separated 8 polyacrylamide gel PAGE transferred PVDF membrane Millipore The membranes blocked 5 nonfat dry milk PBSTween 20 1 h room temperature After incubation polyclonal rabbit antihuman MT PCNA p53 antibody overnight 4 1500 dilution membranes incubated secondary HRP conjugated antirabbit antibody 11000 dilution washed times PBST buffer The transferred proteins visualized ECL detection kit according manufacturers protocol Statistical analysis The SPSS 130 software SPSS Inc Chicago IL United States statistical evaluation The data expressed mean SD 3 independent experiments Statistical significance evaluated analysis variance ANOVA Tukeys post hoc test A P value 005 considered indi cate statistically significant result RESULTS Establishment drugresistant EC9706DDP cells The EC9706DDP cell line established months intermittent exposure parental cells gradually increasing concentration drugs After EC9706 EC9706DDP cells treated DDP concentrations 1 2 4 8 16 32 μgmL 48 h cell viability rate examined MTT assay As shown Figure 1 IC50 48 h DDP EC9706DDP cells 1683 146 μgmL IC50 48 h DDP parental EC9706 cells 334 027 μgmL Therefore EC9706DDP cells times resistant DDP compared parental cells WJGwwwwjgnetcom 1798 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells 24 h 48 h y t l b v l l e C 100 90 80 70 60 50 40 30 20 10 0 0 55 65 75 85 ECRG2 concentration μgmL Figure 2 Survival rate concentrations esophageal cancer related gene 2 A dose time dependent association survival rate EC9706cisplatin DDP cells concentration ECRG2 A longer incubation time ECRG2 significantly decreased survival rate EC9706DDP cells The treatments higher concentration ECRG2 y t l b v l l e C 100 90 80 70 60 50 40 30 20 10 0 DMSO DDP ECRG2 ECRG2 DDP 0 24 48 72 96 th Figure 3 Effects esophageal cancerrelated gene 2 combined cisplatin DDP cell viability EC9706DDP cells Cells treated dimethyl sulfoxide ECRG2 65 μgmL DDP 3 μgmL combination ECRG2 65 μgmL DDP 3 μgmL 24 h 48 h 72 h 96 h Cell viability detected MTT assay Effects ECRG2 EC9706DDP cells To evaluate effects ECRG2 growth viability cells EC9706DDP cells treated concentrations ECRG2 55 65 75 85 μgmL The growth rate cells inhibited dose time dependent manner ECRG2 protein Figure 2 Effects combination treatment ECRG2 DDP EC9706DDP cells Based results 3 μgmL DDP 65 μgmL ECRG2 48 h EC9706DDP cells experiments As shown Figure 3 antiproliferative effect ECRG2 combination DDP better compared ECRG2 DDP These results suggest combination treatment ECRG2 DDP resulted synergistic decrease cell viability compared treatment The inhibition rate combination reached peak 5133 96 h Figure 3 E P I P 104 103 102 101 100 E P I P 104 103 102 101 100 E P I P 104 103 102 101 100 100 101 102 103 104 Annexin Y 100 101 102 103 104 Annexin Y Control DDP E P I P 104 103 102 101 100 100 101 102 103 104 Annexin Y 100 101 102 103 104 Annexin Y ECRG2 DDP ECRG2 ace e t r c t o t p o p y l r E 30 25 20 15 10 5 0 Control DDP ECRG2 DDP ECRG2 Figure 4 Effects esophageal cancerrelated gene 2 combined cisplatin DDP cell apoptosis EC9706DDP cells Cells treated esophageal cancerrelated gene 2 ECRG2 65 μgmL DDP 3 μgmL combination ECRG2 DDP 24 h Early apoptosis determined flow cytometry annexin VPI staining Annexin V set horizontal axis PI set vertical axis Mechanically damaged cells located upper left quadrant apoptotic necrotic cells upper right quadrant dual negative normal cells lower left quadrant early apoptotic cells lower right quadrant flow cytometry dot plot Data shown mean SD aP 005 vs control group cP 005 ECRG2 DDP vs DDP eP 005 ECRG2 DDP vs ECRG2 Effects ECRG2 DDP apoptosis EC9706 DDP cells We examined effect ECRG2 DDP cell apoptosis performing annexin VPI staining The early apoptotic rates control ECRG2 DDP ECRG2 plus DDP groups 571 027 1268 061 1415 087 2796 036 respectively Although treatment groups significantly different control group P 005 combination treatment ECRG2 plus DDP performed significantly better compared ECRG2 DDP P 005 Figure 4 Effects ECRG2 DDP expression PCNA p53 MT mRNA To elucidate mechanisms involved ECRG2 WJGwwwwjgnetcom 1799 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells Ⅰ Ⅱ Ⅲ Ⅰ Ⅱ Ⅲ l e v e l A N R m 3 5 P l e v e l A N R m A N C P 16 14 12 10 08 06 04 02 00 16 14 12 10 08 06 04 02 00 p53 βactin PCNA βactin ce Ⅰ Ⅱ Ⅲ ce Ⅰ Ⅱ Ⅲ Ⅰ Ⅱ Ⅲ MT βactin l e v e l A N R m T M 14 12 10 08 06 04 02 00 Ⅰ Ⅱ Ⅲ Figure 5 Effects esophageal cancerrelated gene 2 cisplatin DDP expression proliferating cell nuclear antigen p53 metallothionein mRNA Ⅰ Drugresistant cell group Ⅱ DDP group Ⅲ DDP esophageal cancerrelated gene 2 ECRG2 group Data expressed mean SD n 3 aP 005 vs control cP 005 vs control eP 005 vs DDP groups combination DDP antiproliferative effects drugresistant cells expression p53 PCNA MT mRNA evaluated cells RT PCR analysis As shown Figure 5 3 μgmL DDP upregulated expression p53 downregulated expression PCNA P 005 When ECRG2 protein combined DDP p53 mRNA expression significantly increased PCNA mRNA expression decreased compared DDP P 005 However changes expression MT mRNA observed Figure 5 Effects ECRG2 DDP expression PCNA p53 MT proteins As shown Figure 6 results western blot consistent RTPCR 3 μgmL DDP upregulated expression p53 protein downregulated expression PCNA protein When WJGwwwwjgnetcom 1800 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells Ⅰ Ⅱ Ⅲ ce Drugresistant cells group Cisplatin group Cisplatin ECRG2 group ce p53 PCNA MT βactin l e v e l n e t o r p e v t e R l 20 19 18 17 16 15 14 13 12 11 10 09 08 07 06 05 04 03 02 01 00 p53 PCNA MT Figure 6 Effects esophageal cancerrelated gene 2 cisplatin DDP expression proliferating cell nuclear antigen p53 metallothionein proteins Ⅰ Drugresistant cell group Ⅱ DDP group Ⅲ DDP esophageal cancerrelated gene 2 ECRG2 group Data expressed mean SD n 3 aP 0 05 vs control cP 005 vs control eP 005 vs DDP groups ECRG2 protein combined DDP expression p53 protein significantly increased expression PCNA protein decreased compared DDP P 005 However changes seen expression MT protein Figure 6 DISCUSSION DDP effective anticancer agents widely treatment solid tumors cluding esophageal cancer Despite consistent rate initial response DDP treatment results development chemoresistance leading therapeutic failure Combination therapy important method overcoming drug resistance There attempts overcome DDP resistance esophageal cancer cells Lee et al12 reported novel oxygen carrier YQ23 enhanced DDP response chemoresistant esophageal tumor xenografts reducing tumor size number animals invasive tumors Lai et al13 provided evidence 1433σ related DNA repair molecule promising therapeutic target counteracting DDP resistance esophageal squamous cell carcinoma Furthermore Yu et al14 suggested autophagy novel target improve efficiency DDP human esophageal cancers acquired resistance In study established EC9706DDP cell line derived vitro treatment sensitive cells model examine effect ECRG2 DDP resistance The results demonstrated combination ECRG2 DDP synergistic inhibitory effects proliferation EC9706DDP cells The inhibition rate significantly higher EC9706DDP cells treated ECRG2 DDP compared cells treated ECRG2 DDP This suggests ECRG2 reduce inhibit DDP resistance 16 15 910 Cui et al The mechanism cancer cells develop resistance chemotherapy associated increased resistance apoptosis Agents induce apoptosis reported sensitize tumor cells DDP reported ECRG2 promoted cell apoptosis vivo vitro Here provided experimental evidence showing combination ECRG2 DDP promoted apoptosis esophageal DDPresistant cancer cells A study Li et al showed ECRG2overexpressing cells higher expression p53 We compared p53 expression levels control DDP ECRG2 plus DDP groups Our results proved p53 involved process The pivotal role p53 proapoptotic function sensitivity The DDP recently reported tumor suppressor protein p53 shown mediate cellular stress response initiate DNA repair cellcycle arrest senescence notably apoptosis However p53 induce DNAdamage promoting cell death Therefore believe combination ECRG2 DDP induced overexpression p53 increased response DDP p53 proapoptotic function esophageal DDPresistant cancer cells 1718 In addition p53 molecules involved DDP resistance Dillehay et al19 reported novel small molecule targeting PCNAinduced DNA damage apoptosis prostate cancer cells enhancing DNA damage apoptosis triggered DDP p53independent manner Expression PCNA genes organisms traditionally associated cell proliferation DNA synthesis genome replication S phase cell cycle20 However recent developments PCNA protein interactions trimer formation signaling regulation allow potential possible therapeutic targeting PCNA21 Both peptides small molecules targeting PCNA signaling reported sensitize cancer cells chemotherapeutic agents2223 A PCNA inhibitor increase DNA doublestrand breaks cause accumulation DNA damage eventually lead cell death cells lack ability repair damage19 In present study demonstrated small WJGwwwwjgnetcom 1801 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells molecule ECRG2 combined DDP reversed DDP resistance downregulating PCNA expression esophageal DDPresistant cancer cells However underlying molecular mechanisms phenomenon require future exploration MT low molecular weight protein rich cysteine24 In recent years relationship MT tumors received increasing attention including role MT tumor formation differentiation proliferation apoptosis tumor cells tumor tissue ammonia chloride DDP chemotherapy drug resistance2526 In vitro vivo studies overexpression MT involved DDP resistance MT expression level DDP resistance level related MT increasing DDP resistance2728 However study demonstrated expression MT related resistance DDP treatment2931 In present study significant change expression MT increasing DDP ECRG2 ECRG2 combination DDP promotes cell apoptosis inhibits cell proliferation reducing expression MT In conclusion showed present study ECRG2 combination DDP reduces inhibits DDP resistance induces cell apoptosis upregulating p53 expression downregulating PCNA expression MT expression Our results suggest combination ECRG2 DDP promising strategy clinical treatment esophageal cancers resistant DDP The effects combined ECRG2 DDP treatment DDPresistant cancer cells investigated confirmed human cancer cell lines animal models cancers COMMENTS COMMENTS Background Cisplatin DDP effective agents esophageal cancer drug resistance poses major impediment Combination therapy important method overcoming drug resistance It reported esophageal cancerrelated gene 2 ECRG2 inhibits tumor cell growth promotes cell apoptosis In previous study ECRG2 combination DDP enhanced inhibitory effect EC9706 cell proliferation increased inductive effect EC9706 cell apoptosis This suggests ECRG2 involved drug resistance esophageal cancer Currently known studies literature examining effects ECRG2 drug resistance esophageal cancer Research frontiers Drug resistance doselimiting effects challenge improvement chemotherapy efficacy These obstacles novel combination therapeutic approaches Anticancer drugs combined broad spectrum molecules smallmolecule inhibitors interfering RNA molecules microRNA oncolytic viruses naturally occurring substances The ECRG2DDP combination presents promising treatment approach Innovations breakthroughs This known study investigate synergistic effect ECRG2 combination DDP In addition current study explores synergy mechanisms ECRG2 DDP DDPresistant esophageal cancer cells Applications This study shows ECRG2 combination DDP inhibit viability induce apoptosis esophageal cancer DDPresistant cells possibly upregulation p53 expression downregulation PCNA expression These findings suggest combination ECRG2 DDP promising strategy clinical treatment esophageal cancers resistant DDP Peerreview This interesting study ECRG2 enhancing anticancer effects DDP DDPresistant esophageal cancer cells REFERENCES 1 Torre LA Bray F Siegel RL Ferlay J LortetTieulent J Jemal A Global cancer statistics 2012 CA Cancer J Clin 2015 65 87108 PMID 25651787 DOI 103322caac21262 Rustgi AK ElSerag HB Esophageal carcinoma N Engl J Med 2014 371 24992509 PMID 25539106 DOI 101056 NEJMra1314530 2 3 Kim M Keam B Kim TM Kim HG Kim JS Lee SS Shin SH Kim MK Park KU Kim DW Yun HJ Lee JS Heo DS Phase II Study Irinotecan Cisplatin Combination Chemotherapy Metastatic Unresectable Esophageal Cancer Cancer Res Treat 2016 Epub ahead print PMID 27488873 DOI 104143 crt2016121 6 5 4 Millar J Scullin P Morrison A McClory B Wall L Cameron D Philips H Price A Dunlop D Eatock M Phase II study gemcitabine cisplatin locally advancedmetastatic oesophageal cancer Br J Cancer 2005 93 11121116 PMID 16278660 DOI 101038sjbjc6602842 Almhanna K Hoffe S Strosberg J Dinwoodie W Meredith K Shridhar R Concurrent chemoradiotherapy protracted infusion 5fluorouracil 5FU cisplatin locally advanced resectable esophageal cancer J Gastrointest Oncol 2015 6 3944 PMID 25642336 DOI 103978jissn207868912014101 Chang H Shin SK Cho BC Lee CG Kim CB Kim DJ Lee JG Hur J Lee CY Bae MK Kim HR Lee SK Park JC Lee H Kim HI Chung H Cha J Lee YC Kim JH A prospective phase II trial S1 cisplatinbased chemoradiotherapy locoregionally advanced esophageal cancer Cancer Chemother Pharmacol 2014 73 665671 PMID 24562525 DOI 101007s002800132371y Pavelic J Editorial combined cancer therapy Curr Pharm Des 2014 20 65116512 PMID 25341927 DOI 102174138161282 0666140826154834 Su T Liu H Lu S Cloning identification cDNA fragments related human esophageal cancer Zhonghua Zhong Liu Za Zhi 1998 20 254257 PMID 10920976 Cui YP Wang JB Zhang XY Bi MX Guo LP Lu SH Using yeast twohybrid identify ECRG2 associated proteins possible interactions ECRG2 gene World J Gastroenterol 2003 9 18921896 PMID 12970870 DOI 103748wjg v9i91892 7 8 9 10 Cui Y Wang J Zhang X Lang R Bi M Guo L Lu SH ECRG2 novel candidate tumor suppressor gene esophageal carcinoma interacts directly metallothionein 2A links apoptosis Biochem Biophys Res Commun 2003 302 904915 PMID 12646258 DOI 101016S0006291X03001220 11 Song HY Deng XH Yuan GY Hou XF Zhu ZD Zhou L Ren MX Expression bcl2 p53 induction esophageal cancer cell apoptosis ECRG2 combination cisplatin Asian Pac J Cancer Prev 2014 15 13971401 PMID 24606472 DOI 107314APJCP20141531397 12 Lee NP Chan KT Choi MY Lam HY Tung LN Tzang FC Han H Lam IP Kwok SY Lau SH Man C Tong DK Wong BL Law S Oxygen carrier YQ23 enhance chemotherapeutic drug responses chemoresistant esophageal tumor xenografts Cancer Chemother Pharmacol 2015 76 11991207 PMID 26553104 DOI 101007s0028001528972 WJGwwwwjgnetcom 1802 March 14 2017Volume 23Issue 10 Hou XF et al Combination ECRG2 DDP DDPresistant EC cells 13 Lai KK Chan KT Choi MY Wang HK Fung EY Lam HY Tan W Tung LN Tong DK Sun RW Lee NP Law S 1433σ confers cisplatin resistance esophageal squamous cell carcinoma cells regulating DNA repair molecules Tumour Biol 2016 37 21272136 PMID 26346170 DOI 101007s1327701540186 14 Yu L Gu C Zhong D Shi L Kong Y Zhou Z Liu S Induction autophagy counteracts anticancer effect cisplatin human esophageal cancer cells acquired drug resistance Cancer Lett 2014 355 3445 PMID 25236911 DOI 101016 jcanlet201409020 15 Zhang R Li Y Dong X Peng L Nie X MiR363 sensitizes cisplatininduced apoptosis targeting Mcl1 breast cancer Med Oncol 2014 31 347 PMID 25416050 DOI 101007 s1203201403473 16 Li MN Huang G Guo LP Lu SH Inhibitory effects esophageal cancer related gene 2 proliferation human esophageal cancer cell EC9706 Zhonghua Yi Xue Za Zhi 2005 85 27852788 PMID 16324322 17 Huang H Chen AY Ye X Li B Rojanasakul Y Rankin GO Chen YC Myricetin inhibits proliferation cisplatinresistant cancer cells p53dependent apoptotic pathway Int J Oncol 2015 47 14941502 PMID 26315556 DOI 103892ijo20153133 18 Li X Huang JM Wang JN Xiong XK Yang XF Zou F Combination chrysin cisplatin promotes apoptosis Hep G2 cells upregulating p53 Chem Biol Interact 2015 232 1220 PMID 25770930 DOI 101016jcbi201503003 19 Dillehay KL Lu S Dong Z Antitumor effects novel small molecule targeting PCNA chromatin association prostate cancer Mol Cancer Ther 2014 13 28172826 PMID 25253786 DOI 10115815357163MCT140522 20 Strzalka W Ziemienowicz A Proliferating cell nuclear antigen PCNA key factor DNA replication cell cycle regulation Ann Bot 2011 107 11271140 PMID 21169293 DOI 101093 aobmcq243 22 21 Wang SC PCNA silent housekeeper potential therapeutic target Trends Pharmacol Sci 2014 35 178186 PMID 24655521 DOI 101016jtips201402004 Inoue A Kikuchi S Hishiki A Shao Y Heath R Evison BJ Actis M Canman CE Hashimoto H Fujii N A small molecule inhibitor monoubiquitinated Proliferating Cell Nuclear Antigen PCNA inhibits repair interstrand DNA crosslink enhances DNA double strand break sensitizes cancer cells cisplatin J Biol Chem 2014 289 71097120 PMID 24474685 DOI 101074jbc M113520429 23 Yu YL Chou RH Liang JH Chang WJ Su KJ Tseng YJ Huang WC Wang SC Hung MC Targeting EGFRPCNA signaling suppresses tumor growth triplenegative breast cancer cells cellpenetrating PCNA peptides PLoS One 2013 8 e61362 PMID 23593472 DOI 101371journalpone0061362 24 Mehus AA Muhonen WW Garrett SH Somji S Sens DA Shabb JB Quantitation human metallothionein isoforms family small highly conserved cysteinerich proteins Mol Cell Proteomics 2014 13 10201033 PMID 24493013 DOI 101074 mcpM113033373 25 Tian ZQ Xu YZ Zhang YF Ma GF He M Wang GY Effects metallothionein3 metallothionein1E gene transfection proliferation cell cycle apoptosis esophageal cancer cells Genet Mol Res 2013 12 45954603 PMID 24222235 DOI 1042382013 26 Zamirska A Matusiak Ł Dziegiel P SzybejkoMachaj G Szepietowski JC Expression metallothioneins cutaneous squamous cell carcinoma actinic keratosis Pathol Oncol Res 2012 18 849855 PMID 22407324 DOI 101007 s1225301295130 27 Kelley SL Basu A Teicher BA Hacker MP Hamer DH Lazo JS Overexpression metallothionein confers resistance anticancer drugs Science 1988 241 18131815 PMID 3175622 DOI 101126science3175622 28 Kennette W Collins OM Zalups RK Koropatnick J Basal zincinduced metallothionein resistance cadmium cisplatin zinc tertbutyl hydroperoxide studies MT knockout antisensedownregulated MT mammalian cells Toxicol Sci 2005 88 602613 PMID 16150881 DOI 101093toxscikfi318 29 Surowiak P Kaplenko I Spaczyński M Zabel M The expression metallothionein MT proliferation intensity ovarian cancers treated cisplatin paclitaxel Folia Morphol Warsz 2003 62 493495 PMID 14655150 30 Tuzel E Yorukoglu K Ozkara E Kirkali Z Association metallothionein expression clinical response cisplatin based chemotherapy testicular germ cell tumors Cent European J Urol 2015 68 4550 PMID 25914837 DOI 105173 ceju201501486 31 Gansukh T Donizy P Halon A Lage H Surowiak P In vitro analysis relationships metallothionein expression cisplatin sensitivity nonsmall cellular lung cancer cells Anticancer Res 2013 33 52555260 PMID 24324058 P Reviewer Kantsevoy S Ong J Tokunaga Y S Editor Qi Y L Editor Rutherford A E Editor Wang CH WJGwwwwjgnetcom 1803 March 14 2017Volume 23Issue 10 Published Baishideng Publishing Group Inc 8226 Regency Drive Pleasanton CA 94588 USA Telephone 19252238242 Fax 19252238243 Email bpgofficewjgnetcom Help Desk httpwwwwjgnetcomespshelpdeskaspx httpwwwwjgnetcom I S S N 1 0 0 7 9 3 2 7 1 0 9 7 7 1 0 07 9 3 2 0 45 2017 Baishideng Publishing Group Inc All rights reserved